x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Mendelspod Podcast

Offering a front row seat to the Century of Biology, veteran podcast host Theral Timpson interviews the who"s who in genomics and genomic medicine. www.mendelspod.com

science & medicine natural sciences

All Episodes

41:27

Elinor Karlsson on Darwin’s Ark

Mendelspod Podcast ·

2023/09/18

Today’s show is made free by the generous support of Twist Bioscience. Twist works in service of people changing the world for the better in fields such as medicine, agriculture, industrial chemicals, and data storage. Their unique silicon-based DNA synthesis platform provides precision that is otherwise unavailable. Check out their products at www.twistbioscience.com. And join them as they write the future of science.Chapters:0:00 Pet dogs have complex genetics and phenotypic data8:00

en

8:12

Long DNA for Difficult Applications: Dan Lin-Arlow,...

Mendelspod Podcast ·

2023/09/13

This is a free preview of a paid episode. To hear more, visit www.mendelspod.comChapters:0:00 World’s longest oligo8:45 Why is it difficult to synthesize long DNA?12:00 Proprietary TdT conjugate16:00 A billion-dollar market24:20 The computation model and its challenges28:35 More customers using generative AIMendelspod is now reader supported. Please consider upgrading to a paid subscription for the price of a couple cof…

en

6:07

Next Gen CRISPR Therapies with Trevor Martin, CEO of...

Mendelspod Podcast ·

2023/09/05

This is a free preview of a paid episode. To hear more, visit www.mendelspod.comChapters:0:00 Novel Cas enzymes help overcome CRISPR challenges11:37 New pipeline of therapies will go after novel targets14:52 How does the new platform open up possibilities for new diagnostics?21:05 What risks do you think about?26:47 What are the company’s two-year goals?31:07 On the possibilitiesCRISPR technology is enabling a new generation …

en

8:25

13th Season Opener: Mike Snyder on Microsampling and...

Mendelspod Podcast ·

2023/08/24

This is a free preview of a paid episode. To hear more, visit www.mendelspod.com0:00 Latest paper on multi-omics microsampling6:30 Is it useful? Two scenarios13:00 How might entrepreneurs bring this to healthcare?18:15 How do you convince physicians?25:48 Are you a reductionist?31:00 Impact of generative AI38:15 Thoughts on the renaissance in proteomicsWe open our 13th season here at Mendelspod with guest, Mike Snyder, S…

en

45:24

Gene Patent Decision at 10 Years, State of Genetic...

Mendelspod Podcast ·

2023/06/15

Ten years ago this week, the Supreme Court unanimously ruled that genes could not be patented. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe

en

33:57

Proteomics Bigger than Genomics, It’s Just Taking...

Mendelspod Podcast ·

2023/06/01

Today we feature Quantum-SI, one of the new wave of proteomics tools companies. The company was founded by serial life science entrepreneur, Jonathan Rothberg, originally as a long read sequencing company. Though the company pivoted to proteomics, they kept the sequencing part. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe

en

39:17

Biden, AI, and DeSci: John Cumbers Previews...

Mendelspod Podcast ·

2023/05/09

SynBioBeta is the largest gathering of the synthetic biology community worldwide. It’s taking place May 23-25 in Oakland, California. John Cumbers is the founder and CEO of the conference, and he joins us to talk about trends in the space and preview this year’s confab.First, we discuss the impact Washington D.C. is having on the field. What doe’s Biden’s love for bio mean for synbio? This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes,

en

30:38

Proteomics Today Where Genomics Was in the 80s:...

Mendelspod Podcast ·

2023/05/08

It’s a thrilling time to be in proteomics. Today we discuss a recent paper in PLOS One demonstrating how new technology has revealed a novel biomarker for non-small cell lung cancer previously undetected by other methods. The paper could be a model for new proteomics research going forward. Our guests are Margaret Donovan, Product Marketing Manager, and Asim Siddiqui, Senior VP of Research, both at proteomics company, Seer. This is a public episode. If you'd like to discuss this with other

en

45:55

Is This New Platform an Answer to the Reproducibility...

Mendelspod Podcast ·

2023/04/27

Philosophers talk about various kinds of knowledge. There is knowing that something is. We learn that the sun is 90 million miles from the Earth. There is also knowing how to do something. This includes skills we learn like riding a bike or cooking spaghetti. Knowing how is different from knowing that. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe

en

30:25

Elegen Pioneers Long DNA Subindustry with CEO Matt Hill

Mendelspod Podcast ·

2023/04/19

Long DNA has arrived. Elegen, a new company based in San Carlos, California, is out this year offering just long DNA. According to their founder and CEO, Matt Hill and today's guest, the company’s product is twenty times more accurate than anything else presently available.What does this mean for the world of biology and the world in general that we're seeing the emergence of a new subindustry devoted specifically to long DNA? This is a public episode. If you'd like to discuss this with other

en

33:04

Nevermind the $200 Genome, Element CEO Molly He Says...

Mendelspod Podcast ·

2023/03/23

"We’re not a sequencing company," says Molly He, CEO and co-founder of Element Biosciences in our first interview with the leader of the hot new sequencing company which seemed to come out of nowhere this past year. “We’re a biology company.”Not a sequencing company? Element has just taken the lead in the race toward cheap clinical genomes, and their CEO is putting that news aside in today’s interview. Instead, she’s much more interested in touting the company’s core technology “avidity.” The term

en

26:52

3D Genomics Solves Cancer Case Where Sequencing Came...

Mendelspod Podcast ·

2023/03/16

Biology is complex, and the life science tool kit continues to expand to meet the challenge of that complexity taking us into the world of multi omics and beyond. Today we talk about 3D genomics and what this additional three-dimensional structural information is telling not just researchers, but clinicians, particularly in oncology. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe

en

23:33

New Spatial Company Maps Cell Surface Proteome...

Mendelspod Podcast ·

2023/03/08

Today we talk with Simon Fredriksson, CEO and co-founder of Pixelgen Technologies, a company just out of stealth offering spatial technology that maps cellular surface proteins at the single cell level. Called molecular pixelation, the breakthrough technology is designed to first target immune cells. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe

en

45:07

John Greally on His Latest Review of Epigenomics

Mendelspod Podcast ·

2023/02/23

Editor's Note: Theral's mic malfunctioned in this interview. Fortunately the not as good backup mic did work and John has a good mic. Our apologies.John Greally joins us today. He is the founding Director of the Albert Einstein College of Medicine’s Center for Epigenomics. He’s a pediatrician and a clinical geneticist with appointments in both at Einstein. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit

en

26:16

President of ASHG on Eugenics Apology, Diversity...

Mendelspod Podcast ·

2023/02/15

Last month the American Society of Human Genetics (ASHG) took a quite remarkable step, putting out a formal statement of apology for its past history of involvement with eugenics. Some say it’s long overdue while some of us didn’t know about this history. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe

en

39:52

23andMe Launches New Personalized Healthcare...

Mendelspod Podcast ·

2023/02/02

23andMe occupies its own place in the world of genomics. Known for its vision to democratize human genomic information, the company has always gone big and bold, and sometimes controversial. Today we don’t hear much controversy—is that because their approach has won out? In any case, they have certainly achieved a scale that surpasses any other genetic testing company. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit

en

31:27

Converting Digital to Biological: John Gill, Telesis Bio

Mendelspod Podcast ·

2023/01/23

Remember all those firsts for synthetic biology that we heard about coming from Craig Venter’s company, Synthetic Genomics in San Diego? The first genome of a whole organism transplanted. First genome synthesized. First synthetic life created. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe

en

33:38

50% Not Tested: Precision Oncology with Jerome...

Mendelspod Podcast ·

2023/01/17

Oncology has emerged as the most successful disease area for precision medicine. Last year, as the genetic testing industry went through a royal shake-up brought on mostly by external market forces, it's been no surprise that precision oncology has been touted as a core strength. As the industry now works "to be more lean and profitable"--new language one hears these days, cancer testing will be a big part of that effort. This is a public episode. If you'd like to discuss this with other

en

37:35

Paul Freemont on Synthetic Biology in the UK

Mendelspod Podcast ·

2023/01/05

To begin the year, we head across the pond for an outlook on the thriving community of synthetic biology in the United Kingdom.Paul Freemont was a co-author of the UK's synthetic biology roadmap and co-directs SynbiCITE, the national center for the commercialization of synthetic biology. A few years ago the government put an initial investment of $300 million pounds into the field, and "everything was going swimmingly well," says Paul. "Then COVID happened." This is a public episode. If you'd

en

40:32

The Bioengineered Hangover Cure: Changing the...

Mendelspod Podcast ·

2022/12/22

Our goal with today’s show was twofold: bring you a practical holiday gift idea and to take you into the world of a synthetic biology entrepreneur. Our guest: Zack Abbott, CEO of ZBiotics.Zack is a scientist turned businessman who is on a mission to change the conversation around GMOs. His first product is a genetically engineered probiotic that alleviates the morning-after hangover by breaking down acetaldehyde. Zack says he chose this product because it’s something consumers can choose to

en

562 results

Similar Podcasts

天方烨谈

基因频道

科学史评话最新专辑

科学史评话

Real Science Radio

Bob Enyart

IDA Space Talks

Ingeniørforeningen, IDA

النشرة العلمية

مونت كارلو الدولية / MCD